The Weight Loss Paradigm Shift

Five years ago, if you mentioned the words “weight loss” to a cardiologist, they’d probably talk about heart-healthy diets, exercise routines, and behavior modification. But something extraordinary happened. A class of medications originally developed to help diabetics control their blood sugar started producing something nobody quite expected: unprecedented weight loss without surgery.

These weren’t the sketchy diet pills from the 1990s. These were serious medications backed by New England Journal of Medicine studies. Patients were losing 15-20% of their body weight. Some were losing even more.

By 2024, one in eight American adults had used a GLP-1 agonist. And that number keeps climbing. In Miami—where beaches, climate, and image consciousness meet—the demand for these medications has exploded. My practice has gone from seeing a handful of GLP-1 patients to managing hundreds. And the questions keep coming: Do they really work? Are they safe? What about all these new peptides everyone’s talking about?

After a decade as a double board-certified cardiologist and internal medicine physician, I’ve learned that the best patient care starts with understanding the actual science. So let’s dig into what these medications really do, what the evidence actually shows, and what you need to know if you’re considering them.

GLP-1 Agonists—How a Diabetes Drug Became a Weight Loss Game-Changer

What is GLP-1, Really?

GLP-1 stands for Glucagon-Like Peptide-1. It’s a hormone your gut naturally produces when you eat, especially when you eat protein or glucose. Its job in your body is to tell your pancreas to release insulin and to tell your brain that you’re full. Simple as that.

But here’s the thing: in people with obesity, this system doesn’t work quite right. The brain doesn’t get the “you’re full” signal as efficiently. The signal gets weaker or the brain stops listening as well. It’s not a character flaw or laziness—it’s a neurobiological problem.

A GLP-1 agonist is a medication that mimics what your body’s natural GLP-1 does, but much more potently and consistently. Think of it as turning up the volume on a signal your body was already trying to send.

How Does It Actually Work?

GLP-1 agonists work through several complementary mechanisms:

• Appetite Suppression: It increases satiety—that feeling of fullness. You eat less because your brain genuinely feels satisfied sooner.
• Slowed Gastric Emptying: Your stomach empties more slowly, so food stays in your stomach longer, and you feel fuller for longer.
• Improved Insulin Sensitivity: Your body’s cells respond better to insulin, meaning your pancreas doesn’t have to work as hard.
• Reduced Food Cravings: Perhaps most importantly, patients report that the obsessive thinking about food—that constant background noise—simply goes away.

From a cardiovascular standpoint (which is my specialty), there’s something else happening too: these medications improve blood pressure, reduce inflammation markers, and improve lipid profiles independently of weight loss. That’s not a side benefit—that’s real cardioprotection.

What the Latest Research Actually Shows

Let’s look at the hard data. In January 2025, researchers published a massive systematic review and meta-analysis in Diabetes Care examining 47 randomized controlled trials involving over 23,000 patients. Here’s what they found:

• GLP-1 agonists produce consistent, dose-dependent weight loss across all populations studied. On average, patients lose 10-20% of their body weight.
• The effect is sustained. Unlike many diets where weight comes back immediately, the weight loss persists as long as patients stay on the medication.
• Improvements extend beyond weight: better blood sugar control, reduced blood pressure, improved lipid profiles.

From a cardiovascular standpoint (which is my specialty), there’s something else happening too: these medications improve blood pressure, reduce inflammation markers, and improve lipid profiles independently of weight loss. That’s not a side benefit—that’s real cardioprotection.

GLP-1 Medications: Current and Emerging Options

For a detailed comparison of these medications, see our guide on GLP-1 vs Dual GLP-1/GIP vs GLP-3 weight loss injections.

Medication	Route	Weight Loss	Key Feature
GLP-1 (Semaglutide)	Weekly injection	~15-17%	Proven cardiovascular benefits
Dual GLP-1/GIP (Tirzepatide)	Weekly injection	~18-22%	Enhanced metabolic effects
GLP-3 (Reta)	Weekly injection	~24-28%	Triple hormone agonist – next generation

The Side Effects—The Honest Conversation

I’m not going to pretend these medications are perfect. As a physician, my job is to be honest about trade-offs.

The most common side effects are gastrointestinal. Nausea, especially when starting or increasing doses. Diarrhea or constipation. These are real, and for some patients, they’re significant enough to stop treatment.

Here’s what I tell my patients: these side effects are usually dose-dependent and tend to improve over time. We start at low doses and increase gradually. Most of my patients who experience nausea report it improves substantially after the first few weeks.

A more recent concern is facial volume loss during rapid weight loss—where the face can appear more gaunt as fat deposits diminish. This is real but manageable through slower dose escalation, maintaining adequate protein intake, and working with an experienced practitioner. It’s not inevitable.

There have been reports of pancreatitis, and thyroid C-cell tumors were noted in animal studies (though human relevance is debated). We screen for thyroid history and monitor patients carefully.

One important note from the cardiovascular perspective: GLP-1 agonists are not recommended in patients with a personal or family history of medullary thyroid cancer or MEN2 syndrome. Period. This is not a gray area.

The Next Level: Dual and Triple Agonists

The evolution of GLP-1 therapy has accelerated dramatically. The newest compounds don’t just target GLP-1—they hit multiple targets simultaneously.

Dual GLP-1/GIP (Tirzepatide): Enhanced Metabolic Control

Learn more about semaglutide for weight loss in Miami.

Dual GLP-1/GIP (Tirzepatide) adds a second hormone to the equation: GIP (Glucose-Dependent Insulinotropic Polypeptide). GIP is another gut hormone that regulates blood sugar and metabolism.

The result? Better weight loss than GLP-1 alone. Clinical trials showed Dual GLP-1/GIP (Tirzepatide) produces approximately 18-22% weight loss, compared to 15-17% with GLP-1 (Semaglutide). That might not sound like a huge difference, but for patients, it often is.

For more on tirzepatide for weight loss in Miami, see our detailed guide.

From my perspective as a cardiologist, what’s interesting is that Dual GLP-1/GIP (Tirzepatide) also provides cardiovascular protection. A 2024 network meta-analysis in Lancet found that among all pharmacological obesity treatments, both GLP-1 and Dual GLP-1/GIP agonists ranked among the best for cardiometabolic benefit.

GLP-3 (Reta): The Triple Agonist—The Future Arrives

For an in-depth look at this breakthrough, read our guide on GLP-3 weight loss injections in Miami.

Now we’re entering genuinely new territory. GLP-3 (also called Reta) adds a third hormone to the mix: glucagon. This combination creates something unprecedented in efficacy.

The numbers are striking. In phase 2 trials published in the 

New England Journal of Medicine (2023) and recently updated in 2025:

• 24.2% mean weight loss at 48 weeks—higher than any GLP-1 or dual agonist
• 90% of participants achieved at least 10% weight loss
• In type 2 diabetic patients: HbA1c reduction of 2.2% with 82% reaching target glucose control
• 72% of prediabetic patients reverted to normal blood sugar

The most recent phase 3 data showed even more impressive results: 28.7% mean weight loss in patients with obesity and joint-related issues, plus significant improvements in pain and physical function.

Is GLP-3 better than GLP-1/GIP agonists? The emerging evidence suggests yes, at least for weight loss. But it’s still in development—FDA approval is predicted for 2027. By the time you’re reading this, that timeline may have shifted.

Weight-Loss Peptides—Beyond GLP-1s

Beyond GLP-1 agonists, Miami is seeing growing interest in peptides for fitness goals and metabolic optimization. Here’s where things get interesting—and where I need to be very careful with the science.

GLP-1 agonists are medications. They’ve gone through FDA trials. Tirzepatide is approved. Semaglutide is approved. But in Miami’s wellness community, people are talking about other peptides for weight loss and metabolic optimization. Some have real evidence. Some… don’t. Let me separate fact from fiction.

MOTS-c: The Cellular Energy Peptide

MOTS-c (Mitochondrial-derived Peptide-c) is a natural peptide your mitochondria (your cells’ power plants) produce. It regulates energy metabolism at the cellular level.

What’s interesting: MOTS-c levels decline with age, and low MOTS-c is associated with metabolic dysfunction and obesity. What if you could restore it?

Recent 2025 research published in Frontiers in Physiology showed that administering MOTS-c to diabetic mice improved mitochondrial function and prevented excessive weight gain. In aging models, MOTS-c improved pancreatic function and slowed cellular aging markers.

Is MOTS-c a weight-loss drug? Not yet. It’s in early investigational stages. But the mechanism is real, and clinical research is expanding.

NAD+ and NMN: The Energy and Longevity Peptides

NAD+ is a coenzyme your cells use to produce energy. NMN is its precursor. Unlike most peptides we’re discussing, NAD+/NMN boosters actually have human clinical trial data.

A 2024 meta-analysis in Food Frontiers examined 9 randomized controlled trials (412 total participants) and found that NMN supplementation:

• Improved walking speed in older adults by approximately 7%
• Increased muscle mass when combined with exercise
• Improved metabolic markers in people with metabolic dysfunction

Is NMN a weight-loss agent? Not directly. But improved metabolic function and increased muscle mass support long-term weight management. The effect is modest but real and supported by human data.

BPC-157: The Healing Peptide (And Why Caution is Warranted)

BPC-157 has become something of a celebrity in fitness and wellness circles. Everyone from podcasters to CrossFit athletes is talking about it. But here’s my honest take as a physician: the hype has wildly outpaced the evidence.

What BPC-157 is: A 15-amino-acid peptide naturally found in your stomach. In animal studies (mostly rats and mice), it appears to promote tissue healing through various mechanisms.

What the evidence actually shows: A 2025 systematic review analyzing 544 studies found that BPC-157 consistently promoted healing in animal models—tendons, ligaments, muscles, bones, all showed improvement. The mechanisms involve growth factor activation, new blood vessel formation, and inflammation reduction.

Here’s the critical part: virtually all of this data is from animals. The human data is… sparse.

A 2025 comprehensive review identified only one published randomized controlled trial in humans (for ulcerative colitis), plus two small case series with 12-14 participants total. That’s it. And some of those small trials were conducted at private clinics with financial interest in promoting the peptide.

The regulatory status: In late 2023, the FDA classified BPC-157 as a Category 2 bulk drug substance—meaning it cannot be compounded by commercial pharmacies and there is “insufficient evidence to know whether the drug would cause harm to humans.”

It’s also banned by WADA (World Anti-Doping Agency) in sports.

My position: BPC-157 is an interesting research area. The preclinical science suggests real potential. But using it outside of an FDA-sanctioned clinical trial is choosing to be a test subject for something we don’t fully understand yet. That’s not evidence-based medicine. That’s experimentation.

Why Your Cardiologist Matters in Weight Loss

You might be wondering: why am I a cardiologist writing about weight loss medications?

Because weight, metabolic health, and cardiovascular health are inseparable. Obesity doesn’t just cause weight gain—it damages blood vessels, increases inflammation, raises blood pressure, and creates metabolic dysfunction that directly harms the heart.

At Dr. Sende Wellness in Miami, our approach to weight loss is comprehensive. Yes, we use GLP-1 agonists. Yes, we use the newer dual and triple agonists for appropriate patients. But we also:

• Conduct detailed cardiovascular assessment before starting any medication—these drugs improve heart health, but we want to make sure we’re starting from a safe baseline
• Order comprehensive metabolic and inflammatory markers to understand the full metabolic picture
• Monitor kidney function (GLP-1s are safe for kidneys, but we verify this)
• Integrate medical nutrition therapy—medication isn’t a substitute for dietary improvement
• Optimize exercise prescription to maximize results and preserve muscle

We also believe in transparency. We discuss side effects honestly. We don’t oversell results. We monitor patients regularly with repeat labs to ensure safety.

Part 3: Practical Questions Patients Ask

Question: “How quickly will I lose weight?”

Weight loss typically starts within 2-4 weeks, but it’s often modest at first. More significant loss happens weeks 6-12 as doses increase. Peak weight loss usually occurs around 6-12 months on a stable dose.

Question: “What happens if I stop the medication?”

This is important: if you stop GLP-1 agonists, weight typically returns. This isn’t failure—it’s biology. The medication was addressing an underlying dysregulation. Stopping it doesn’t fix that dysregulation.

That said, the weight gain isn’t usually immediate or complete. Many patients maintain a portion of their weight loss long-term, especially if they’ve made dietary changes and maintained exercise during treatment. Microdosing can help negate the effects of quitting completely.

Question: “Can I use these medications with other medications?”

Generally yes, but there are interactions to consider. GLP-1s slow stomach emptying, which can affect when other medications are absorbed. If you’re on diabetes medications, doses may need adjustment as you lose weight and your insulin sensitivity improves. This is why we monitor carefully.

Question: “What about muscle loss?”

Rapid weight loss can include muscle loss. We mitigate this through three strategies: (1) adequate protein intake (our nutritionist recommends 1g per pound of ideal body weight), (2) resistance exercise, and (3) gradual rather than rapid dose escalation.

Question: “What’s the cost?”

GLP medications start at approximately $30/week. Insurance coverage varies dramatically. Some plans cover it; others don’t. We work with patients to explore all available options to make treatment accessible.

The Bottom Line

We’re living through a genuine paradigm shift in how we treat obesity. For the first time in decades, we have medications that produce meaningful, sustained weight loss with real cardioprotective benefits.

GLP-1 agonists and the newer dual/triple agonists are evidence-based. They work. The research is solid.

Other peptides? Some are promising (NAD+/NMN has human trial data). Others are interesting but not yet proven in humans. Be cautious about claims that outpace evidence.

If you’re in Miami and considering these options, my advice: work with someone who understands not just weight loss, but metabolic and cardiovascular health. Get tested. Get monitored. Start carefully. Combine medication with real lifestyle change.

These medications are tools, not magic. But in the hands of an experienced physician? They can genuinely change lives.

About Dr. Sende Wellness

Dr. Fernando Fandiño-Sende is a double board-certified physician in cardiology and internal medicine. His practice, Dr. Sende Wellness in Miami, specializes in evidence-based weight loss, metabolic optimization, and peptide therapy. To learn more about our medical weight loss programs in Miami, visit us. Located at 1063 SW Eighth Street, Miami, FL 33130.

Phone: (786) 655-0187

Email: office@drsende.com

Website: DrSende.com

Both in-office and telemedicine consultations available.

Scientific Sources & References

The claims in this article are based on peer-reviewed research. Click the links above throughout the article to access the sources, or see the full list below:

GLP-1 Agonists: Meta-Analysis and Efficacy

Wong et al. (2025) – “Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference for Patients With Obesity or Overweight: A Systematic Review, Meta-analysis, and Meta-regression of 47 Randomized Controlled Trials.” Diabetes Care 48, no. 2 (2025): 292–300. https://diabetesjournals.org/care/article/48/2/292/157724/

GLP-3 (Reta): Triple Agonist Research

Jastreboff et al. (2023) – “Triple-Hormone-Receptor Agonist for Obesity — A Phase 2 Trial.” New England Journal of Medicine 389 (2023): 1181-1192. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972

Real-World Evidence on GLP-1s

Thomsen et al. (2025) – “Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.” Diabetes, Obesity and Metabolism 27 (2025): 2214-2222. https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.16364

MOTS-c: Mitochondrial Peptide Research

Pham et al. (2025) – “Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart.” Frontiers in Physiology 16 (2025): 1421389. https://www.frontiersin.org/articles/10.3389/fphys.2025.1421389

NAD+ and NMN Research

Yang et al. (2025) – “An Updated Review on the Mechanisms, Pre-Clinical and Clinical Comparisons of NMN and NR.” Food Frontiers 4 (2025): 1-25. https://onlinelibrary.wiley.com/doi/10.1002/fft2.403

BPC-157 Systematic Review

Vasireddi et al. (2025) – “Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.” Orthopaedic Surgery 17, no. 4 (2025): 1089-1108. https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/